Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study

Affiliations

• ¹ Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
• ² Division of Hematology & Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
• ³ Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
• ⁴ Department of Hematology, Japanese Red Cross Society, Suwa Hospital, Suwa, Japan.
• ⁵ Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
• ⁶ Department of Hematology, University Hospital of Nantes, Nantes, France.
• ⁷ Department of Medicine, University of California, San Francisco, CA, USA.
• ⁸ Sanofi, Research and Development, Vitry-Sur-Seine, France.
• ⁹ Sanofi, Research and Development, Tokyo, Japan.
• ¹⁰ Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
• ¹¹ Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.